Home > Publications Database > Metabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmission. > print

001     268317
005     20240403113236.0
024 7 _ |a pmc:PMC10881642
|2 pmc
024 7 _ |a 10.1007/s00259-023-06493-w
|2 doi
024 7 _ |a pmid:37971501
|2 pmid
024 7 _ |a 1619-7070
|2 ISSN
024 7 _ |a 1619-7089
|2 ISSN
024 7 _ |a altmetric:156504360
|2 altmetric
037 _ _ |a DZNE-2024-00199
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Stockbauer, Anna
|0 P:(DE-2719)9002610
|b 0
|e First author
|u dzne
245 _ _ |a Metabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmission.
260 _ _ |a Heidelberg [u.a.]
|c 2024
|b Springer-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1709031182_12962
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Metabolic network analysis of FDG-PET utilizes an index of inter-regional correlation of resting state glucose metabolism and has been proven to provide complementary information regarding the disease process in parkinsonian syndromes. The goals of this study were (i) to evaluate pattern similarities of glucose metabolism and network connectivity in dementia with Lewy bodies (DLB) subjects with subthreshold dopaminergic loss compared to advanced disease stages and to (ii) investigate metabolic network alterations of FDG-PET for discrimination of patients with early DLB from other neurodegenerative disorders (Alzheimer's disease, Parkinson's disease, multiple system atrophy) at individual patient level via principal component analysis (PCA).FDG-PETs of subjects with probable or possible DLB (n = 22) without significant dopamine deficiency (z-score < 2 in putamen binding loss on DaT-SPECT compared to healthy controls (HC)) were scaled by global-mean, prior to volume-of-interest-based analyses of relative glucose metabolism. Single region metabolic changes and network connectivity changes were compared against HC (n = 23) and against DLB subjects with significant dopamine deficiency (n = 86). PCA was applied to test discrimination of patients with DLB from disease controls (n = 101) at individual patient level.Similar patterns of hypo- (parietal- and occipital cortex) and hypermetabolism (basal ganglia, limbic system, motor cortices) were observed in DLB patients with and without significant dopamine deficiency when compared to HC. Metabolic connectivity alterations correlated between DLB patients with and without significant dopamine deficiency (R2 = 0.597, p < 0.01). A PCA trained by DLB patients with dopamine deficiency and HC discriminated DLB patients without significant dopaminergic loss from other neurodegenerative parkinsonian disorders at individual patient level (area-under-the-curve (AUC): 0.912).Disease-specific patterns of altered glucose metabolism and altered metabolic networks are present in DLB subjects without significant dopaminergic loss. Metabolic network alterations in FDG-PET can act as a supporting biomarker in the subgroup of DLB patients without significant dopaminergic loss at symptoms onset.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a DaT-Scan
|2 Other
650 _ 7 |a Dementia with Lewy bodies
|2 Other
650 _ 7 |a FDG-PET
|2 Other
650 _ 7 |a Metabolic connectivity
|2 Other
650 _ 7 |a Dopamine
|0 VTD58H1Z2X
|2 NLM Chemicals
650 _ 7 |a Fluorodeoxyglucose F18
|0 0Z5B2CJX4D
|2 NLM Chemicals
650 _ 7 |a Glucose
|0 IY9XDZ35W2
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Lewy Body Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Dopamine: metabolism
|2 MeSH
650 _ 2 |a Fluorodeoxyglucose F18
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Glucose: metabolism
|2 MeSH
650 _ 2 |a Metabolic Networks and Pathways
|2 MeSH
700 1 _ |a Beyer, Leonie
|b 1
700 1 _ |a Huber, Maria
|b 2
700 1 _ |a Kreuzer, Annika
|b 3
700 1 _ |a Palleis, Carla
|0 P:(DE-2719)9000852
|b 4
|u dzne
700 1 _ |a Katzdobler, Sabrina
|0 P:(DE-2719)9001160
|b 5
700 1 _ |a Rauchmann, Boris Stephan
|0 P:(DE-2719)9001808
|b 6
|u dzne
700 1 _ |a Morbelli, Silvia
|b 7
700 1 _ |a Chincarini, Andrea
|b 8
700 1 _ |a Bruffaerts, Rose
|b 9
700 1 _ |a Vandenberghe, Rik
|b 10
700 1 _ |a Kramberger, Milica G
|b 11
700 1 _ |a Trost, Maja
|b 12
700 1 _ |a Garibotto, Valentina
|b 13
700 1 _ |a Nicastro, Nicolas
|b 14
700 1 _ |a Lathuilière, Aurélien
|b 15
700 1 _ |a Lemstra, Afina W
|b 16
700 1 _ |a van Berckel, Bart N M
|b 17
700 1 _ |a Pilotto, Andrea
|b 18
700 1 _ |a Padovani, Alessandro
|b 19
700 1 _ |a Ochoa-Figueroa, Miguel A
|b 20
700 1 _ |a Davidsson, Anette
|b 21
700 1 _ |a Camacho, Valle
|b 22
700 1 _ |a Peira, Enrico
|b 23
700 1 _ |a Bauckneht, Matteo
|b 24
700 1 _ |a Pardini, Matteo
|b 25
700 1 _ |a Sambuceti, Gianmario
|b 26
700 1 _ |a Aarsland, Dag
|b 27
700 1 _ |a Nobili, Flavio
|b 28
700 1 _ |a Gross, Mattes
|b 29
700 1 _ |a Vöglein, Jonathan
|0 P:(DE-2719)2811820
|b 30
|u dzne
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 31
|u dzne
700 1 _ |a Pogarell, Oliver
|b 32
700 1 _ |a Buerger, Katharina
|0 P:(DE-2719)2811351
|b 33
|u dzne
700 1 _ |a Franzmeier, Nikolai
|0 P:(DE-2719)2811119
|b 34
700 1 _ |a Danek, Adrian
|0 P:(DE-2719)2810712
|b 35
|u dzne
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 36
|u dzne
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 37
|u dzne
700 1 _ |a Bartenstein, Peter
|b 38
700 1 _ |a Cumming, Paul
|b 39
700 1 _ |a Rominger, Axel
|b 40
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 41
|e Last author
773 _ _ |a 10.1007/s00259-023-06493-w
|g Vol. 51, no. 4, p. 1023 - 1034
|0 PERI:(DE-600)2098375-X
|n 4
|p 1023 - 1034
|t European journal of nuclear medicine and molecular imaging
|v 51
|y 2024
|x 1619-7070
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP2.docx
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP3.xlsx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/268317/files/DZNE-2024-00199.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/268317/files/DZNE-2024-00199.pdf?subformat=pdfa
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP1.doc
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP1.odt
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP2.doc
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP2.odt
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP2.pdf
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP3.csv
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP3.ods
856 4 _ |u https://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP3.xls
909 C O |o oai:pub.dzne.de:268317
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002610
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9000852
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001160
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 6
|6 P:(DE-2719)9001808
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2811820
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)2812234
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 33
|6 P:(DE-2719)2811351
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 34
|6 P:(DE-2719)2811119
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 35
|6 P:(DE-2719)2810712
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 36
|6 P:(DE-2719)2811659
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 37
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 41
|6 P:(DE-2719)9001539
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-23
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-23
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2023-08-23
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-23
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-23
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-23
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-23
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-23
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 1
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 2
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1110008
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)5000022
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21